Open original FDA record ↗Recall record
- FDA identifier
- Z-2226-2021
- Company in FDA record
- Biomerieux Inc
- FDA record creation date
- Aug 6, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.
Source facts
- Action
- The recall notification was issued to the impacted subsidiaries and distributors on 24JUN2021. The notification includes a Customer Letter to be translated into local language and sent to each impacted customer. The customer letter will inform the customers about the MIC overestimation and false resistant results issue and will be instructed to: - Perform a retest using an alternative method on P. aeruginosa strains for which they obtained resistant or intermediate results with ETEST IMIPENEM RELEBACTAM ref. 420925 and 420927 - Among tests previously performed, identify any possible false resistant/intermediate results that may have occurred, to analyze the related risks and to determine appropriate actions if relevant.
- Initiated
- 2021-06-24
- Root cause
- Under Investigation by firm
- Terminated
- 2025-02-10
- Distribution
- Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, NC, NE, NH, NJ, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WA, WI, WV and Hawaii. The countries of Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.
- Recall number
- Z-2226-2021
- Recall status
- Terminated
- CDRH record ID
- 188207
- FDA record created
- 2021-08-06
- Recall event number
- 88242